Health & Fitness
Health and Fitness
Health and Fitness
Tue, May 31, 2011
Mon, May 30, 2011
Fri, May 27, 2011 InSite Vision to Webcast Annual Meeting of Stockholders on June 1, 2011
ALAMEDA, Calif.--([ BUSINESS WIRE ])--InSite Vision Incorporated (OTCBB: INSV) will hold its Annual Meeting of Stockholders at 10:00 a.m. Pacific Time on Wednesday, June 1, 2011 at the company's headquarters at 965 Atlantic Avenue, Alameda, California. Company management will host a webcast beginning at 10:00 a.m. PDT/1:00 p.m. EDT which will be available on the Investor Relations page of the company's website at [ www.insitevision.com ].
To access the webcast of the meeting, go to the InSite Investor Relations site at [ http://phx.corporate-ir.net/phoenix.zhtml?c=86061&p=irol-calendar ] and click on the event link. For those who miss the live broadcast, an archived replay will be available shortly thereafter.
Analysts and investors can participate via conference call by dialing 877-407-8035 for domestic callers and 201-689-8035 for international callers. A telephone replay will be available following the conclusion of the call by dialing 877-660-6853 for domestic callers and 201-678-7415 for international callers. All callers will need to enter the account number 286 and conference ID # 373186.
About InSite Vision
InSite Vision is advancing new and superior ophthalmologic products for unmet eye care needs. The companya™s product portfolio utilizes InSite Visiona™s proven DuraSite® bioadhesive polymer core technology, an innovative platform that extends the duration of drug retention on the surface of the eye, thereby reducing frequency of treatment and improving the efficacy of topically delivered drugs. The DuraSite platform is currently leveraged in two commercial products for the treatment of bacterial eye infections, AzaSite® (azithromycin 1% ophthalmic solution), marketed in the U.S. by Merck & Company, Inc., and Besivance® (besifloxacin 0.6% ophthalmic suspension), marketed by Bausch & Lomb and their partner Pfizer Inc. InSite Visiona™s clinical-stage ophthalmic product pipeline includes AzaSite Plusa" (ISV-502) and DexaSitea" (ISV-305) for the treatment of eye infections, ISV-303 for pain and swelling associated with ocular surgery, and ISV-101 for the treatment of dry eye disease. For further information on InSite Vision, please visit [ www.insitevision.com ].
